Golam Mohi
Golam Mohi
Associate Professor

Department of Pharmacology
Upstate Medical University


PhD 2001 University of Tokyo, Japan
Postdoctoral Fellow 2005 Harvard Medical School, USA




Research Interest

Stem cell biology, cell signaling, hematopoiesis and blood cancer 


Professional Activities:

  • American Society of Hematology (ASH)
  • American Association for Cancer Research (AACR)



  1. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
  2. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
  3. The role of Shp2 (PTPN11) in cancer.
  4. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer.
  5. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
  6. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.
  7. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
  8. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
  9. Critical role for Gab2 in transformation by BCR/ABL.
  10. Analysis of mechanisms involved in the prevention of gamma irradiation-induced apoptosis by hGM-CSF.
  11. Activation and functional analysis of Janus kinase 2 in BA/F3 cells using the coumermycin/gyrase B system.
  12. Monoclonal antibodies to the enterotoxin of Bacteroides fragilis: production, characterization, and immunodiagnostic application.
  13. Production, characterization and immunodiagnostic application of a monoclonal antibody to Shiga toxin.


cancer-research Journal Flyer